Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/ABL2_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/ABL2_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/ABL2_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/ABL2_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/ABL2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/ABL2_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/ABL2_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/ABL2_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/ABL2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003297010 | Cervix | CC | regulation of actin filament-based process | 96/2311 | 397/18723 | 4.00e-11 | 8.54e-09 | 96 |
GO:003295610 | Cervix | CC | regulation of actin cytoskeleton organization | 86/2311 | 358/18723 | 5.90e-10 | 7.51e-08 | 86 |
GO:00510566 | Cervix | CC | regulation of small GTPase mediated signal transduction | 75/2311 | 302/18723 | 1.54e-09 | 1.74e-07 | 75 |
GO:00072656 | Cervix | CC | Ras protein signal transduction | 79/2311 | 337/18723 | 9.49e-09 | 7.77e-07 | 79 |
GO:00315328 | Cervix | CC | actin cytoskeleton reorganization | 31/2311 | 107/18723 | 3.34e-06 | 8.99e-05 | 31 |
GO:00109757 | Cervix | CC | regulation of neuron projection development | 88/2311 | 445/18723 | 4.26e-06 | 1.09e-04 | 88 |
GO:00313467 | Cervix | CC | positive regulation of cell projection organization | 72/2311 | 353/18723 | 1.04e-05 | 2.32e-04 | 72 |
GO:00072666 | Cervix | CC | Rho protein signal transduction | 35/2311 | 137/18723 | 1.77e-05 | 3.33e-04 | 35 |
GO:00465785 | Cervix | CC | regulation of Ras protein signal transduction | 44/2311 | 189/18723 | 2.05e-05 | 3.73e-04 | 44 |
GO:00301008 | Cervix | CC | regulation of endocytosis | 47/2311 | 211/18723 | 3.65e-05 | 5.82e-04 | 47 |
GO:20002493 | Cervix | CC | regulation of actin cytoskeleton reorganization | 14/2311 | 39/18723 | 1.36e-04 | 1.66e-03 | 14 |
GO:00105067 | Cervix | CC | regulation of autophagy | 61/2311 | 317/18723 | 2.61e-04 | 2.87e-03 | 61 |
GO:00350235 | Cervix | CC | regulation of Rho protein signal transduction | 22/2311 | 86/18723 | 5.93e-04 | 5.60e-03 | 22 |
GO:00510585 | Cervix | CC | negative regulation of small GTPase mediated signal transduction | 15/2311 | 56/18723 | 2.60e-03 | 1.80e-02 | 15 |
GO:00350244 | Cervix | CC | negative regulation of Rho protein signal transduction | 8/2311 | 22/18723 | 3.43e-03 | 2.22e-02 | 8 |
GO:00465804 | Cervix | CC | negative regulation of Ras protein signal transduction | 13/2311 | 49/18723 | 5.34e-03 | 3.10e-02 | 13 |
GO:0032970 | Colorectum | AD | regulation of actin filament-based process | 142/3918 | 397/18723 | 4.05e-12 | 5.90e-10 | 142 |
GO:0032956 | Colorectum | AD | regulation of actin cytoskeleton organization | 127/3918 | 358/18723 | 1.03e-10 | 1.04e-08 | 127 |
GO:0010506 | Colorectum | AD | regulation of autophagy | 111/3918 | 317/18723 | 3.57e-09 | 2.35e-07 | 111 |
GO:0007265 | Colorectum | AD | Ras protein signal transduction | 104/3918 | 337/18723 | 1.01e-05 | 2.35e-04 | 104 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ABL2 | SNV | Missense_Mutation | | c.679N>T | p.Asp227Tyr | p.D227Y | P42684 | protein_coding | deleterious(0) | probably_damaging(0.979) | TCGA-A2-A04W-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
ABL2 | SNV | Missense_Mutation | novel | c.2929N>G | p.Arg977Gly | p.R977G | P42684 | protein_coding | tolerated_low_confidence(0.11) | possibly_damaging(0.483) | TCGA-A2-A0EQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
ABL2 | SNV | Missense_Mutation | novel | c.703N>C | p.Glu235Gln | p.E235Q | P42684 | protein_coding | deleterious(0.02) | possibly_damaging(0.726) | TCGA-A2-A0YH-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
ABL2 | SNV | Missense_Mutation | novel | c.404N>A | p.Arg135Gln | p.R135Q | P42684 | protein_coding | tolerated(0.1) | benign(0.38) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
ABL2 | SNV | Missense_Mutation | | c.1835N>A | p.Arg612Lys | p.R612K | P42684 | protein_coding | tolerated_low_confidence(0.92) | benign(0.076) | TCGA-BH-A0HL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
ABL2 | SNV | Missense_Mutation | rs752266744 | c.730N>T | p.Leu244Phe | p.L244F | P42684 | protein_coding | deleterious(0.03) | probably_damaging(1) | TCGA-D8-A1JD-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
ABL2 | SNV | Missense_Mutation | | c.1363N>C | p.Glu455Gln | p.E455Q | P42684 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-E2-A1LG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
ABL2 | SNV | Missense_Mutation | novel | c.2630N>T | p.Pro877Leu | p.P877L | P42684 | protein_coding | deleterious_low_confidence(0.01) | benign(0.01) | TCGA-EW-A1IZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxotere | SD |
ABL2 | insertion | Frame_Shift_Ins | novel | c.2993_2994insA | p.Cys999LeufsTer68 | p.C999Lfs*68 | P42684 | protein_coding | | | TCGA-A8-A07R-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Ancillary | zoledronic | SD |
ABL2 | insertion | Frame_Shift_Ins | novel | c.2992_2993insACAGCCAGCTGGTAGACACTGGACACCAGCTGCTTGAC | p.Ile998AsnfsTer25 | p.I998Nfs*25 | P42684 | protein_coding | | | TCGA-A8-A07R-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Ancillary | zoledronic | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
27 | ABL2 | KINASE, TYROSINE KINASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, ENZYME | | DASATINIB | DASATINIB | |
27 | ABL2 | KINASE, TYROSINE KINASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, ENZYME | inhibitor | TOZASERTIB | TOZASERTIB | 19035792 |
27 | ABL2 | KINASE, TYROSINE KINASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, ENZYME | | PONATINIB | PONATINIB | 20513156 |
27 | ABL2 | KINASE, TYROSINE KINASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, ENZYME | | DASATINIB | DASATINIB | |
27 | ABL2 | KINASE, TYROSINE KINASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, ENZYME | | DASATINIB | DASATINIB | 25207766 |
27 | ABL2 | KINASE, TYROSINE KINASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, ENZYME | | IMATINIB | IMATINIB | 25207766 |
27 | ABL2 | KINASE, TYROSINE KINASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, ENZYME | inhibitor | 249565827 | | |
27 | ABL2 | KINASE, TYROSINE KINASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, ENZYME | inhibitor | 363894211 | PEXMETINIB | |